Exercise Program During Chemotherapy in Metastatic Colorectal Cancer

Sponsor
University of Southern California (Other)
Overall Status
Terminated
CT.gov ID
NCT03111823
Collaborator
National Cancer Institute (NCI) (NIH)
2
2
1
23.9
1
0

Study Details

Study Description

Brief Summary

This pilot clinical trial studies how well aerobic exercise works in improving quality of life and health-related outcomes in patients with stage IV colorectal cancer undergoing chemotherapy. Aerobic exercise during chemotherapy may improve quality of life and reduce fatigue and inflammation in the blood related to heart disease and diabetes in patients with stage IV colorectal cancer.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Exercise Intervention
  • Other: Quality-of-Life Assessment
  • Other: Questionnaire Administration
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. To determine whether a 6-week indoor or outdoor aerobic exercise program is feasible in patients with metastatic colorectal cancer (mCRC) undergoing chemotherapy and to explore patient's preferences for indoor versus (vs.) outdoor exercise.

  2. To determine the effects of a 6-week indoor or outdoor aerobic exercise program on cancer-related fatigue and quality of life (QOL) in patients with mCRC.

SECONDARY OBJECTIVES:
  1. To determine the effects of a 6-week indoor or outdoor aerobic exercise program on body composition (lean body mass, fat mass, body fat percentage [%]) and biomarkers of systemic inflammation (interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-a], C-reactive protein [CRP]) in patients with mCRC.
TERTIARY OBJECTIVES:
  1. To determine the effects of a 6-week exercise program on cardiovascular (CV) function.
OUTLINE:

Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.

After completion of study treatment, patients are followed up for 6 weeks and at weeks 13, 19, and 31.

Study Design

Study Type:
Interventional
Actual Enrollment :
2 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Feasibility of a 6-Week Aerobic Exercise Program During Chemotherapy for Metastatic Colorectal Cancer
Actual Study Start Date :
Jul 7, 2016
Actual Primary Completion Date :
Jul 5, 2018
Actual Study Completion Date :
Jul 5, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Supportive Care (aerobic exercise)

Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.

Behavioral: Exercise Intervention
Undergo aerobic exercise sessions

Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
  • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies

    Outcome Measures

    Primary Outcome Measures

    1. Total number of minutes exercised per week with >80% total weekly minutes (48/60 minutes) completed [Up to 6 weeks]

      The study will assess the feasibility using average weekly minutes of exercise completion (minutes/week) of all participants. Feasibility will be determined based on the total number of minutes exercised per week with >80% total weekly minutes (48/60 minutes) completed deeming this trial as feasible.

    Secondary Outcome Measures

    1. Change in biomarkers of systemic inflammation [Baseline up to 31 weeks]

      Change in biomarkers will be examined by a paired sample t-test, with a level of significance set at p <0.05.

    2. Change in cancer-related fatigue [Baseline up to 31 weeks]

      Assessed by the National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale

    3. Change in QOL [Baseline up to 31 weeks]

      Assessed by the Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C)

    Other Outcome Measures

    1. Change in arterial stiffness/geometry [Baseline up to 31 weeks]

      Assessed by ultrasound

    2. Change in endothelial function [Baseline up to 31 weeks]

      Assessed by flow-mediated dilation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Newly diagnosed metastatic (stage IV) colorectal cancer

    • Undergoing chemotherapy (have had 1 or 2 chemotherapy cycles infused at time of data collection; this will allow for any systemic inflammatory changes due to chemotherapy to set in); only patients with 1st or 2nd line therapy will be included

    • Able to initiate a supervised exercise program (free from any CV, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity)

    • Free from uncontrolled chronic disease including diabetes, hypertension, or thyroid disease

    • Currently participate in less than 60 minutes of physical activity/week

    • Willing to travel to the exercise facility at University of Southern California (USC) (parking fees and public transportation permits will be provided)

    • Speak English or Spanish

    Exclusion Criteria:
    • Uncontrolled hypertension or other uncontrolled chronic disease (e.g. diabetes mellitus, thyroid disease, pulmonary disease, etc)

    • Moderate to highly active level of physical activity (e.g. currently participating in

    60 minutes of moderate aerobic activity weekly)

    • Orthopedic or other restrictions or contraindications to exercise

    • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

    • Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Los Angeles County-USC Medical Center Los Angeles California United States 90033
    2 USC / Norris Comprehensive Cancer Center Los Angeles California United States 90033

    Sponsors and Collaborators

    • University of Southern California
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Christina Dieli-Conwright, Ph.D., University of Southern California

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Southern California
    ClinicalTrials.gov Identifier:
    NCT03111823
    Other Study ID Numbers:
    • 3C-16-1
    • NCI-2016-01089
    • 3C-16-1
    • P30CA014089
    First Posted:
    Apr 13, 2017
    Last Update Posted:
    Aug 13, 2018
    Last Verified:
    Aug 1, 2018
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 13, 2018